Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma-Reference-Cited by-同舟云学术

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Published:2021-09-29 Issue:3 Volume:195 Page:388-398
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Topp Max S.¹,Meerten Tom²³,Houot Roch⁴,Minnema Monique C.³⁵,Bouabdallah Krimo⁶,Lugtenburg Pieternella J.³⁷^ORCID,Thieblemont Catherine⁸,Wermke Martin⁹,Song Kevin W.¹⁰,Avivi Irit¹¹,Kuruvilla John¹²^ORCID,Dührsen Ulrich¹³^ORCID,Zheng Yan¹⁴,Vardhanabhuti Saran¹⁴,Dong Jinghui¹⁴,Bot Adrian¹⁴,Rossi John M.¹⁴,Plaks Vicki¹⁴,Sherman Marika¹⁴,Kim Jenny J.¹⁴,Kerber Anne¹⁴,Kersten Marie José³¹⁵

Affiliation:

1. Medizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany

2. University Medical Center Groningen GroningenThe Netherlands

3. On Behalf of HOVON/LLPC (Lunenburg Lymphoma Phase I/II Consortium)

4. CHU Rennes University of Rennes Inserm & EFS Rennes France

5. University Medical Center Utrecht Utrecht The Netherlands

6. CHU Bordeaux, Service d’Hématologie et Thérapie Cellulaire Bordeaux France

7. Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands

8. Université de Paris, AP‐HP, Hôpital Saint Louis, Hemato‐Oncology, DMU HI, Research Unit NF‐kappaB, Différenciation et Cancer Paris France

9. NCT/UCC Early Clinical Trial Unit University Hospital Carl Gustav Carus Dresden Germany

10. The University of British Columbia Vancouver Canada

11. Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

12. Princess Margaret Cancer Centre University of Toronto Toronto Canada

13. University Hospital Essen Essen Germany

14. Kite, A Gilead Company Santa Monica CA USA

15. Amsterdam UMC University of Amsterdam Amsterdam The Netherlands

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17673

Reference34 articles.

1. YESCARTA®(axicbatagene ciloleucel) Summary of product characteristics. Kite Pharma EU B.V.; 2021.

2. YESCARTA®(axicabtagene ciloleucel) Prescribing information.Kite Pharma Inc;2021.

3. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

4. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

5. Long‐term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi‐cel);Jacobson C;Blood,2020

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma;Transplantation and Cellular Therapy;2024-08

2. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy;Seminars in Immunopathology;2024-07-16

3. Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma;2024-07-02

4. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome;Clinical Neurophysiology;2024-07

5. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity;Blood Advances;2024-06-25